Clarus Wealth Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Clarus Wealth Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-500	Closed	-$16K	–	164
2019 Q3	$16K	Hold	500	–	–	0.01%	143
2019 Q2	$11K	Hold	500	–	–	0.01%	430
2019 Q1	$19K	Hold	500	–	–	0.01%	428
2018 Q4	$23K	Hold	500	–	–	0.04%	383
2018 Q3	$22K	Hold	500	–	–	0.01%	422
2018 Q2	$14K	Hold	500	–	–	0.01%	483
2018 Q1	$14K	Buy	+500	New	+$18.6K	0.01%	126

Other funds holding VTGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Clarus Wealth Advisors's VTGN Position: Q4 2019 in Review

Clarus Wealth Advisors sold out of VistaGen Therapeutics (VTGN) in Q4 2019, closing a stake of 500 shares — an estimated $16K sold.

Clarus Wealth Advisors first reported a position in VTGN in Q1 2018 and held it in 7 quarters. The position peaked at $23K in Q4 2018. 25 funds tracked by Wall St. Rank hold VTGN as of Q4 2019.

Clarus Wealth Advisors reported no remaining VistaGen Therapeutics position as of Q4 2019 after selling out during the quarter.
Clarus Wealth Advisors sold 500 VistaGen Therapeutics shares in Q4 2019, an estimated $16K.
Clarus Wealth Advisors first reported a position in VistaGen Therapeutics in Q1 2018 and held it in 7 quarters.
Clarus Wealth Advisors's VistaGen Therapeutics position peaked at $23K in Q4 2018.
25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2019.

Based on Clarus Wealth Advisors's 13F filing for Q4 2019, filed 10 Jan 2020.